Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Overview of attention for article published in New England Journal of Medicine, January 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 27 news outlets
blogs: 1 blog
policy: 3 policy sources
twitter: 122 X users
patent: 22 patents

facebook: 3 Facebook pages
wikipedia: 1 Wikipedia page
video: 1 YouTube creator
guideline: 4 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 483 Mendeley

So far, Altmetric has seen 22 patents that reference this research output.

Ferroportin inhibitors for use in the treatment of myelodysplastic syndrome (MDS)

Grant JP-7886880-B2

Japan

08 Jul 2026

Activin receptor type IIA variants and methods of use thereof

Grant US-12582700-B2

United States of America

24 Mar 2026

Activin receptor type II chimeras and methods of use thereof

Grant US-12522646-B2

United States of America

13 Jan 2026

Methods of using activin receptor type IIB variants

Grant US-12440539-B2

United States of America

14 Oct 2025

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 18 additional patents.